Chemotherapy-induced Nausea and Vomiting

Mustian, Karen M.; Darling, Tom V.; Janelsins, Michelle Christine; Jean‐Pierre, Pascal; Morrow, Gary R.

doi:10.17925/ohr.2008.04.1.19

Cited by 11 publications

(12 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…94,95 Adherence to these guidelines improves control of CINV by approximately 20%. 96 Chemotherapy regimens are classified into four categories according to potential for CINV—highly emetogenic (>90%), moderately emetogenic (both with and without anthracycline and cyclophosphamide [AC]; 30–90%), low emetogenic (10–30%), and minimally emetogenic (<10%).…”

Section: Clinical Guidelinesmentioning

confidence: 99%

Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients

Janelsins¹,

Tejani²,

Kamen³

et al. 2013

Expert Opinion on Pharmacotherapy

Self Cite

134

110

View full text Add to dashboard Cite

Introduction Nausea and vomiting are two of the most frequent and troubling side effects patients experience during chemotherapy, interfering with compliance with cancer therapies and quality of life. While newly available treatments have improved our ability to manage nausea and vomiting, anticipatory and delayed nausea and vomiting are still major problems for patients receiving chemotherapy. Many cancer patients consider delaying future chemotherapy cycles and some contemplate stopping chemotherapy altogether because of their fear of experiencing further nausea and vomiting. Areas Covered The purpose of this article is to provide an overview of the patho-psychophysiology of chemotherapy-induced nausea and vomiting, the recommended guidelines for treatment, current agents in late-stage clinical trials, and future research needs to address the continued challenges of treatment-related nausea and vomiting. Expert Opinion Despite advances in pharmaceutical and behavioral therapies, and the provision of standard clinical guidelines for effectively managing chemotherapy-induced nausea and vomiting (CINV), patients continue to experience CINV. Moreover, control of nausea, acute and delayed, and anticipatory nausea and vomiting (ANV) remains an important, unmet need among cancer patients. It is critical to focus attention on better understanding the mechanisms underlying nausea, anticipatory symptoms, and delayed symptoms.

show abstract

Section: Clinical Guidelinesmentioning

confidence: 99%

Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients

Janelsins¹,

Tejani²,

Kamen³

et al. 2013

Expert Opinion on Pharmacotherapy

Self Cite

134

110

View full text Add to dashboard Cite

show abstract

“…Chemotherapy‐induced nausea and vomiting (CINV) is a common complication of anticancer treatment, experienced in the absence of prophylaxis by >90% of patients administered highly emetogenic chemotherapy such as cisplatin and anthracycline/cyclophosphamide combinations and by 30%–90% of patients administered moderately emetogenic chemotherapy such as carboplatin . These symptoms interfere with a patient's quality of life and ability to function and, as a result, may disrupt treatment adherence . Thus, active prophylaxis of CINV is a critical component of supportive care for patients with cancer at risk for emesis who are receiving emetogenic cancer chemotherapy.…”

mentioning

confidence: 99%

“…Thus, active prophylaxis of CINV is a critical component of supportive care for patients with cancer at risk for emesis who are receiving emetogenic cancer chemotherapy. Uncontrolled CINV may result in anticipatory nausea and vomiting, a conditioned response reported in up to 30% of patients by their fourth cycle of chemotherapy . Furthermore, patients who experience acute or anticipatory CINV are at greater risk of recurrence in subsequent chemotherapy cycles …”

mentioning

confidence: 99%

Bioequivalence of Intravenous and Oral Rolapitant: Results From a Randomized, Open‐Label Pivotal Study

Wang

Zhang

Powers

et al. 2017

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Rolapitant, a selective and long-acting neurokinin-1 receptor antagonist, is approved in an oral formulation for the prevention of delayed chemotherapy-induced nausea and vomiting in adults. The objective of this pivotal study was to assess the bioequivalence of a single intravenous infusion of rolapitant versus a single oral dose of rolapitant. In this randomized, open-label phase 1 study, healthy volunteers were administered rolapitant as a 180-mg oral dose or a 30-minute 166.5-mg intravenous infusion. Blood samples for pharmacokinetic analysis were collected predose and at points up to 912 hours postdose. Criteria for bioequivalence of the intravenous dose versus the oral dose were met if the 90% confidence intervals (CIs) for the ratios of the geometric least-squares means (GLSMs) for the area under the plasma concentration-time curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC ) and AUC from time 0 extrapolated to infinity (AUC ) for rolapitant were within 0.80-1.25. Mean rolapitant systemic exposure and half-lives were similar in the oral (n = 62) and intravenous (n = 61) rolapitant groups. The 90%CIs of the ratio of GLSMs were within the 0.80-1.25 range for AUC (0.94-1.09) and AUC (0.93-1.10). The incidence of treatment-emergent adverse events, all mild or moderate in severity, was similar in the intravenous and oral groups. A 166.5-mg intravenous infusion of rolapitant met the bioequivalence criteria based on AUC to a 180-mg oral dose and was well tolerated.

show abstract

“…5,6 Chemotherapy-induced nausea and vomiting remain 2 of the most distressing side effects experienced by cancer patients. 7,8 In fact, studies report the prevalence of these adverse symptoms ranges from 13% to 75%. 9 Consequently, they can lead to poorer chemotherapy adherence, diminished quality of life, increased depression and anxiety, and increased use of public health resources.…”

mentioning

confidence: 99%

The Effects of the Bali Yoga Program for Breast Cancer Patients on Chemotherapy-Induced Nausea and Vomiting: Results of a Partially Randomized and Blinded Controlled Trial

Anestin

Dupuis

Lanctôt

et al. 2017

J Evid Based Complementary Altern Med

View full text Add to dashboard Cite

Complementary and alternative medicine has been shown to be beneficial in reducing chemotherapy-induced nausea and vomiting. However, conclusive results are lacking in order to confirm its usefulness. The purpose of this study was to determine whether a standardized yoga intervention could reduce these adverse symptoms. This was a partially randomized and blinded controlled trial comparing a standardized yoga intervention with standard care. Eligible patients were adults diagnosed with stages I to III breast cancer receiving chemotherapy. Patients randomized to the experimental group participated in an 8-week yoga program. There was no significant difference between the experimental and control groups on chemotherapy-induced nausea and vomiting after 8 weeks. Results suggest the yoga program is not beneficial in managing these adverse symptoms. However, considering preliminary evidence suggesting yoga’s beneficial impact in cancer symptom management, methodological limitations should be explored and additional studies should be conducted.

show abstract

Chemotherapy-induced Nausea and Vomiting

Cited by 11 publications

References 76 publications

Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients

Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients

Bioequivalence of Intravenous and Oral Rolapitant: Results From a Randomized, Open‐Label Pivotal Study

The Effects of the Bali Yoga Program for Breast Cancer Patients on Chemotherapy-Induced Nausea and Vomiting: Results of a Partially Randomized and Blinded Controlled Trial

Contact Info

Product

Resources

About